Palle Schelde Jensen

LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark.

Inventure Capital A/S is a venture capital firm based in Aarhus, Denmark. Founded in 2006, the firm was established to manage several early-stage technology funds, namely INCUBA Venture, InnFond and Syddansk Kapital.

ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.

DNA Diagnostic A/S manufactures and supplies oligonucleotides. The company was founded by Steen Lovmand in 1992 and is headquartered in Risskov, Denmark.

Proxeon Biosystems ApS develops and sells technology, equipment, and supplies for biotechnology and clinical research. The company was founded by Ole Vorm on October 31, 2002 and is headquartered in Roskilde, Denmark.

Fluxome, a Copenhagen-based Danish company, is a recognized leader in the field of industrial biotechnology. Fluxome uses its proprietary, cutting-edge microbial metabolic engineering technology platform to build highly efficient cell factories for the production of a broad range of commercially important nutraceutical ingredients. Fluxome's technology allows the company to rapidly develop and commercialize high purity, natural products manufactured using cost-effective bioprocesses.

FCMB, based in Vejle, Denmark, is a molecular diagnostics company that develops a system for prenatal genetic analysis. FCMB is committed to developing new, no risk diagnostic method to assess genetic abnormalities, such as Down syndrome. Their team includes world-class scientists within the field of fetal cell research and experts in prenatal testing.

Anapa Biotech A/S provides molecular tools to enhance the performance of natural nucleic acids. Its technology is the proprietary Twisted Intercalating Nucleic Acid molecules. The company was founded by Gorm Lisby and Henrik Westh in 2002 and is headquartered in Hørsholm, Denmark.